Quest Diagnostic Receives the US FDA’s First EUA for Sample Pooling in COVID-19

 Quest Diagnostic Receives the US FDA’s First EUA for Sample Pooling in COVID-19

Quest Diagnostic Receives the US FDA’s First EUA for Sample Pooling in COVID-19

Shots:

  • The US FDA has authorized Quest SARS-CoV-2 rRT-PCR test for use with pooled samples containing up to 4 individual swab specimens collected under observation. The Quest test is the first COVID-19 diagnostic test to be authorized for use with pooled samples
  • Quest Diagnostic expects to deploy the technique at its laboratories in Chantilly, VA and Marlborough, Mass., by the end of next week with additional laboratories to follow
  • The company has received the FDA’s EUA for use of self-collection molecular diagnostic kit on the Hologic and Roche’s platforms, expanding use with healthcare provider supervision via telemedicine

Click here to read full press release/ article | Ref: PRNewswire | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post